Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation

Taru Hallinen,1 Erkki Soini,1 Christian Asseburg,1 Miika Linna,2 Pia Eloranta,3 Sari Sintonen,3 Mikko Kosunen3 1ESiOR Oy, Kuopio, Finland; 2Aalto University, Department of Industrial Engineering and Management, Espoo, Finland; 3Pfizer Oy, Helsinki, FinlandCorrespondence: Taru Hallinen ESiOR Oy, Tull...

Full description

Bibliographic Details
Main Authors: Hallinen T, Soini E, Asseburg C, Linna M, Eloranta P, Sintonen S, Kosunen M
Format: Article
Language:English
Published: Dove Medical Press 2021-08-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
apixaban
cost-utility
dabigatran
economic evaluation
rivaroxaban
warfarin
Online Access:https://www.dovepress.com/cost-effectiveness-of-apixaban-versus-other-direct-oral-anticoagulants-peer-reviewed-fulltext-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-of-apixaban-versus-other-direct-oral-anticoagulants-peer-reviewed-fulltext-article-CEOR

Similar Items